Combioxin SA
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.combioxin.com
Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae
Phase 1
Completed
- Conditions
- PneumoniaPneumococcal Infections
- Interventions
- Drug: CAL02 Low-doseDrug: CAL02 High-doseDrug: Placebo
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Combioxin SA
- Target Recruit Count
- 19
- Registration Number
- NCT02583373
- Locations
- π§πͺ
University Hospital Brussels, Brussels, Belgium
π§πͺClinique St Pierre, Ottignies, Belgium
π«π·CHU Jean Minjoz, Besancon, France
Β© Copyright 2025. All Rights Reserved by MedPath